AbbVie has announced a $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus. The facilities will integrate advanced manufacturing technologies and artificial intelligence to support production of next-generation neuroscience and
Cross-border licensing deals between Greater China-based biopharmaceutical companies and global drugmakers reached an unprecedented $137.7 billion in 2025, a nearly tenfold increase from 2021’s $13.9 billion, according to China-based data provider PharmCube. Industry analysts now predict 2026 will surpass that
The FDA officially launched its Manufacturing PreCheck Pilot Program on February 1, 2026, introducing a two-phase regulatory framework designed to accelerate construction and approval of new U.S. pharmaceutical manufacturing facilities. The initiative arrives as the contract development and manufacturing organization
SK bioscience has announced that it will advance a novel respiratory syncytial virus (RSV) preventive monoclonal antibody under a licence agreement with the Gates Medical Research Institute (Gates MRI). The clinical-stage candidate is intended for the prevention of RSV infection
AstraZeneca began trading on the New York Stock Exchange on Monday, February 2, 2026, marking a significant shift in the pharmaceutical giant’s U.S. market strategy as it ended its American Depositary Shares program on Nasdaq. The UK-based drugmaker delisted its
Eli Lilly and Company has announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will be used to produce injectable medicines and devices, including next-generation weight-loss therapies such as
AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and research and development capabilities, with a strategic focus on cell therapies and radioconjugates. The announcement came on Thursday, 29th January during UK Prime Minister
Boehringer Ingelheim and Simcere Pharmaceutical Group have signed a licence and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD). The partnership aims to advance the candidate through global development. SIM0709
MS Pharma Group has entered into a strategic partnership with Hetero Group to localize five established biosimilars across oncology, immunology, and hematology in Algeria. The agreement aims to expand access to biologic medicines through a localization and technology transfer approach.
Genentech, a member of the Roche Group, has expanded its investment in a new manufacturing facility in Holly Springs, North Carolina, increasing the total commitment to around $2 billion. The move builds on an initial investment announced in May 2025
